Drug intelligence / Profile preview

Refresh (Artivila Biopharma)

Development stage: Preclinical
Lead developer: Artivila Therapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

**Refresh** is an uncharacterized discovery-stage small-molecule drug candidate developed by Artivila Biopharma for inflammatory bowel disease and neurodegenerative diseases. Publicly available program records identify it as a small molecule and list these two active therapeutic areas, but do not disclose a chemical structure, INN, molecular target, mechanism of action, formulation, route of administration, manufacturer, or clinical protocol. Artivila describes its broader portfolio as AI- and computer-aided-design-enabled small-molecule drug discovery focused on autoimmune, neurodegenerative, and cancer indications. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/868ba83bd5994106a3014d159a5ab23d))

Beyond the preview

Go deeper on Refresh (Artivila Biopharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refresh (Artivila Biopharma).

Explore the full profile